Data/hora: 10/06/2024 06:24:17

Provedor de dados: 	55	
País: 	Brazil	
Título: 	Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir	
Autores: 	Machado,Daisy Maria; Gouvêa,Aída de Fátima Barbosa; Cardoso,Maria Regina; Beltrão,Suênia Vasconcelos; Cunegundes,Kelly Simone; Bononi,Fabiana; Almeida,Fernanda; Cavalheiro,Kaline; Angelis,Daniela Souza Araújo de; Succi,Regina Célia de Menezes.	
Data: 	2007-02-01	
Ano: 	2007	
Palavras-chave: 	HIV; Children; HAART; Lopinavir/ritonavir.	
Resumo: 	This study evaluates clinical, virological and immunological responses to antiretroviral (ARV) therapy based on Lopinavir/ritonovir (LPV/r) in previously protease -inhibitor-experienced children. The study included 29 Brazilian children (median age = 5.91 years) who had failed previous ARV therapy and had begun a regimen based on LPV/r. At 12 months follow-up, a good virological response to LPV/r therapy was defined as achieving an undetectable viral load or as a decrease in plasma HIV RNA levels to &gt; 1 log. A good immunological response was defined as an increase in CD4+ cell count from baseline sufficient to attain a better CDC immune stage classification. The number of infectious episodes 12 months before and 12 months after beginning LPV/r was assessed. Sixteen (55.2%) and 19 (65.5%) of 29 patients exhibited good virological and immunological responses, respectively. Baseline CD4+ values (&gt;500) predicted both virological and immunological responses (p&lt;0.05). Older children were less likely to develop an immunological response (p&lt;0.001) than younger children. Nine children receiving 3 ARV drugs plus LPV/r showed an immunological response (100%) compared to 10/20 (50%) children receiving 2 drugs plus LPV/r (p=0.01). A lower number (n&lt;5) of infectious episodes was noted after 12 months follow-up in children using the LPV/r regimen (p=0.006). There was a positive correlation between children whose baseline CD4+ values were greater than 500 cells/mm³ and virological responses. Although virological responses to therapy were seen in about half the children (55.2%), the use of HAART containing LPV/r provided clinical and immmunological benefits.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000100006	
Editor: 	Brazilian Society of Infectious Diseases	
Relação: 	10.1590/S1413-86702007000100006	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Infectious Diseases  v.11 n.1 2007	
Fonte: 	info:eu-repo/semantics/openAccess